Guillermo Garcia-Manero, MD | Authors

KROGER PHARMACY #707

2010 WHITTAKER RD

Articles

Guillermo Garcia-Manero, MD, on Eprenetapopt-Azacytidine Combo in TP53+ MDS

June 18, 2020

The MD Anderson expert discussed the phase 3 trial – designed to evaluate frontline eprenetapopt in combination with azacytidine (Vidaza) in patients with TP53-mutant positive myelodysplastic syndrome (MDS) – that recently completed full enrollment.

Myelodysplastic Syndromes

June 01, 2016

Myelodysplastic syndromes (MDS) are a group of hematologic malignancies of the pluripotent hematopoietic stem cells. These disorders are characterized by ineffective hematopoiesis, including abnormalities in proliferation, differentiation, and apoptosis.

Cancer Management Chapter 32: Myelodysplastic syndromes

March 13, 2010

Myelodysplastic syndromes (MDS) are a group of hematologic malignancies of the pluripotent hematopoietic stem cells. These disorders are characterized by ineffective hematopoiesis, including abnormalities in proliferation, differentiation, and apoptosis. The overall clinical phenotype is peripheral cytopenias in the setting of a normocellular or hypercellular bone marrow and an increased risk for transformation to acute leukemia.

Management of Myelodysplastic Syndromes: Just the Beginning

November 01, 2008

Drs. Scott and Estey provide an excellent, concise review of current diagnostic and therapeutic approaches for patients with myelodysplastic syndromes (MDS). Both physicians are recognized world leaders in this area.